Research programme: CNS disorder therapeutics - BioXcel Corporation

Drug Profile

Research programme: CNS disorder therapeutics - BioXcel Corporation

Alternative Names: BXCL 501; BXCL 502

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Agitation; CNS disorders

Most Recent Events

  • 17 Apr 2017 Preclinical trials in Agitation in USA (Sublingual) (BioXcel Corporation pipeline, April 2017)
  • 17 Apr 2017 BioXcel plans a clinical trial for Agitation in USA (BioXcel Corporation website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top